MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2019 International Congress

    Ixcellence Network®, an International Innovative Educational Programme To Improve Cervical Dystonia And Spastic Paresis Management: Feedback survey from 839 attendees

    C. Colosimo, TM. Chung, LJ. Jacinto, K. Bhatia, A. Fulford-Smith, R. Bhidayasiri (Roma, Italy)

    Objective: To assess the Ixcellence Network® training programme educative quality and impact on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis…
  • 2019 International Congress

    High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy

    S. Chiu, B. Patel, M. Burns, J. Legacy, A. Shukla, A. Ramirez-Zamora, W. Deeb, I. Malaty (Gainesville, FL, USA)

    Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…
  • 2019 International Congress

    OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study

    A. Esquenazi, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, W. Jost (Elkins Park, PA, USA)

    Objective: To examine the impact of onabotulinumtoxinA treatment in adult patients with spasticity on caregiver burden over 2 years from the Adult Spasticity International Registry…
  • 2018 International Congress

    5 Years’ Experience of Ixcellence Network®, an International Innovative Educational Program to improve Cervical Dystonia and Spastic paresis Management Practices

    C. Colosimo, T.M. Chung, L.J. Jacinto, K. Bahtia, T. Landreau, R. Bhidayasiri (Roma, Italy)

    Objective: To describe the impact of the Ixcellence® Network training program on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis (SP).…
  • 2018 International Congress

    First Results from the Ixcellence Network® Survey: Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis

    R. Bhidayasiri, K. Bahtia, L.J. Jacinto, TM. Chung, T. Landreau, C. Colosimo (Bangkok, Thailand)

    Objective: To describe the current situation of training and practices among physicians using botulinum neurotoxin-A (BoNT-A) injections in the treatment of Cervical Dystonia (CD) and…
  • 2018 International Congress

    “Appropriate Doses Treatment” of IncobotulinumtoxinA in spasticity

    G. Ianieri, R. Marvulli (Bari, Italy)

    Objective: The aim of this study is to object the efficiency and safety of 100 to 1000 units botulinum toxin treatment with modulation of spasticity…
  • 2018 International Congress

    Evaluation of Effectiveness and Safety of Botulinum Toxin Type-A (BTX-A) for Chronic Focal Post-Stroke Upper Limb Spasticity in Indian Stroke Patients

    L. Basumatary (Guwahati, India)

    Objective: To evaluate the effectiveness and safety of Botulinum Toxin Type-A (BTX-A) for the treatment chronic focal post-stroke upper limb spasticity in Indian stroke patients.…
  • 2017 International Congress

    A Comparison of Muscular Atrophy Between Botulinum Toxin Types A and B

    F. Amjad, F. Pagan, A. Lax, C. Moussa (Washington DC, DC, USA)

    Objective: To compare and quantify the degree of muscular atrophy (MA) in botulinum toxin (BT) type A (Botox) and type B (Myobloc). A secondary endpoint…
  • 2017 International Congress

    The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results

    G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

    Objective: To evaluate the 1-year interim onabotulinumtoxinA safety, effectiveness, and exploratory treatment utilization data from the ASPIRE study. Background: OnabotulinumtoxinA treatment for patients with spasticity…
  • 2017 International Congress

    The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity

    G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

    Objective: To examine the treatment patterns of onabotulinumtoxinA utilization in patients treated for upper and lower limb spasticity, in combination, from the ASPIRE study (1…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28953 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley